Boston, MA, United States of America

Matthew James Wathier

This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Valo Health, Inc.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Matthew James Wathier. Retrieved from https://idiyas.com/inventor/matthew-james-wathier

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Matthew James Wathier: Inventor in Pharmaceutical Chemistry.

Introduction

Matthew James Wathier is an inventor associated with Boston, Massachusetts, and Valo Health, Inc. His patent work concerns chemical processes and compounds relevant to pharmaceutical research.

Latest Patents

Wathier is named on 1 patent: “Process for Preparing 6-Substituted-1-(2H)-Isoquinolinones and Intermediate Compound.” The invention describes substituted isoquinoline oxide compounds and a process for preparing them. These compounds can serve as intermediates in producing 6-substituted-1-(2H)-isoquinolinones, which inhibit the enzyme Rho-kinase or can be used to prepare further Rho-kinase inhibitors.

Career Highlights

Wathier’s listed patent reflects work on synthetic methods and intermediate compounds with potential applications in developing Rho-kinase inhibitors. He is associated with Valo Health, Inc.

Collaborations

His listed coworkers include Par Holmberg and Sumit Kumar.

Conclusion

Matthew James Wathier’s patent contribution focuses on preparing chemical intermediates for compounds that inhibit Rho-kinase, connecting his inventive work with pharmaceutical research.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…